SCHEMBL16858283

SCHEMBL16858283

COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(CCP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 13/20 0.82
▸ PLK4 O00444 3/20 0.82
▸ AURKA O14965 3/20 0.82
▸ RET P07949 3/20 0.82
▸ FLT3 P36888 3/20 0.82
▸ MAPK8 P45983 3/20 0.82
▸ MAPK9 P45984 3/20 0.82
▸ MST1R Q04912 3/20 0.82
▸ PTK2 Q05397 3/20 0.82
▸ IKBKE Q14164 3/20 0.82
▸ STK16 O75716 2/20 0.82
▸ TNK1 Q13470 2/20 0.82
▸ MAP3K11 Q16584 2/20 0.82
▸ ADCK1 Q86TW2 2/20 0.82
▸ PIP4K2C Q8TBX8 2/20 0.82
▸ NEK9 Q8TD19 2/20 0.82
▸ AURKB Q96GD4 2/20 0.82
▸ IRAK3 Q9Y616 2/20 0.82
▸ LATS1 O95835 1/20 0.82
▸ BRDT Q58F21 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28489482 0.93 SYK (0.84) SYKPLK4AURKARETFLT3
Water SCHEMBL29088767 0.91 SYK (0.82) SYKPLK4AURKARETFLT3
Fostamatinib SCHEMBL29351337 0.90 SYK (1.00) SYKPLK4AURKARETFLT3
Fostamatinib SCHEMBL1201371 0.90 SYK (1.00) SYKPLK4AURKARETFLT3
SCHEMBL4108129 0.90 SYK (0.81) SYKPLK4AURKARETFLT3
SCHEMBL13451994 0.89 SYK (0.91) SYKPLK4AURKARETFLT3
Fostamatinib SCHEMBL22164570 0.89 SYK (0.99) SYKPLK4AURKARETFLT3
Fostamatinib SCHEMBL16820327 0.89 SYK (0.99) SYKPLK4AURKARETFLT3
SCHEMBL16682499 0.89 SYK (0.80) SYKPLK4AURKARETFLT3
SCHEMBL13984998 0.89 SYK (0.89) SYKPLK4AURKARETFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9388203-B2 Pharmaceutical process and intermediates MIDCAP FINANCIAL TRUST 2016-07-12 — — US disclosed
US-20150175639-A1 Pharmaceutical Process and Intermediates MIDCAP FINANCIAL TRUST 2015-06-25 — — US disclosed
US-20150175639-A1 Pharmaceutical Process and Intermediates MIDCAP FINANCIAL TRUST 2015-06-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150175639-A1 Pharmaceutical Process and Intermediates CYP3A4, UGT1A10, CYP3A5 SYK 2361/4885PLK4 528/4885AURKA 1479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback